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Introduction
In 1962, Norman Stoll, the distinguished Rockefeller Institute 
scientist who helped to establish human parasitology research 
in North America, described the unique health impact of 
hookworm as follows [1]:
As it was when I ﬁ rst saw it, so it is now, one of the most evil 
of infections. Not with dramatic pathology as are ﬁ lariasis, or 
schistosomiasis, but with damage silent and insidious. Now that 
malaria is being pushed back hookworm remains the great 
infection of mankind. In my view it outranks all other worm 
infections of man combined…in its production, frequently 
unrealized, of human misery, debility, and inefﬁ ciency in the 
tropics.
Like many other global disease experts who witnessed 
dramatic reductions in malaria prevalence as a result of DDT 
spraying during the late 1950s [2], Stoll did not anticipate 
malaria’s imminent re-emergence in India. However, he 
articulated with eloquence the magnitude of the disease 
burden resulting from hookworm infection. He further 
offered the silent and insidious character of hookworm as 
a partial explanation for its neglect by the global medical 
community. 
This neglect subsequently intensiﬁ ed during the 1970s, 
1980s, and 1990s with the omission of hookworm from the 
list of diseases covered by the World Health Organization’s 
Special Programme for Research and Training in Tropical 
Diseases, as well as from other global health initiatives. 
Over the last ten years, however, there has been increasing 
recognition of the global health importance of hookworm. 
Today, new international efforts to control the morbidity of 
hookworm and other soil-transmitted helminth infections are 
in progress (www.who.int/wormcontrol). 
Etiology and Global Distribution
Human hookworm infection is caused by blood-feeding 
nematode parasites of the genus Ancylostoma and the 
species Necator americanus. Worldwide, N. americanus is 
the predominant etiology of human hookworm infection, 
whereas A. duodenale occurs in more scattered focal 
environments [3]. These two hookworms, together with the 
roundworm, Ascaris lumbricoides, and the whipworm, Trichuris 
trichiura, are often referred to collectively as soil-transmitted 
helminths (STHs).
No international surveillance mechanisms are in place 
to determine the prevalence and global distribution of 
hookworm infection. However, based on an extensive 
search of the literature since 1990, the worldwide number 
of cases of hookworm was recently estimated to be 740 
million people [4]. The highest prevalence of hookworm 
occurs in sub-Saharan Africa and eastern Asia (Figure 1). 
High transmission (deﬁ ned below) also occurs in other 
areas of rural poverty in the tropics, including southern 
China [5], the Indian subcontinent [6], and the Americas 
[7]. In all regions, there is a striking relationship between 
hookworm prevalence and low socioeconomic status (Figure 
2) [4]. Hookworm’s neglected status partly reﬂ ects its 
concentration among the world’s poorest 2.7 billion people 
who live on less than $2 a day. 
Clinical Features, Epidemiology, and Disease Burden
Hookworm infection is acquired by invasion of the infective 
larval stages through the skin (A. duodenale larvae are also 
orally infective). Following host entry, the larvae undergo a 
journey through the vasculature, then the lungs and other 
tissues, before they enter the gastrointestinal tract and molt 
twice to become one-centimeter-long adult male and female 
worms [3]. The worms mate and the female hookworms 
produce up to 30,000 eggs per day, which exit the host’s body 
in the feces (Figure 3). 
Because hookworms do not replicate in humans, the 
morbidity of hookworm is highest among patients that harbor 
large numbers of adult parasites. Estimates of the intensity 
of hookworm infection are typically obtained by using 
quantitative fecal egg counts as a surrogate marker for worm 
burden. The World Health Organization deﬁ nes moderate-
intensity infections as those with 2,000–3,999 eggs per gram 
of feces, and heavy-intensity infections as those with 4,000 or 
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Hookworm has proven to be extremely 
diffi cult to eliminate or eradicate in 
areas of poverty and poor sanitation.
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more eggs per gram (p. 26 in [8]). Compared to other STH 
infections and schistosomiasis, hookworm infection exhibits 
a unique age-intensity proﬁ le—whereas the intensities for 
the former peak in childhood and adolescence, hookworm 
intensity usually either steadily rises in intensity with age or 
plateaus in adulthood [3,9]. The biological basis for this 
observation is unknown [10].
Adult hookworms cause morbidity in the host by producing 
intestinal hemorrhage [3].  The adult hookworms then 
ingest the blood, rupture the erythrocytes, and degrade 
the hemoglobin [11]. Therefore, the disease attributed to 
hookworm is silent blood loss leading to iron deﬁ ciency 
anemia and protein malnutrition. There is a correlation 
between parasite intensity and host intestinal blood loss 
[12]; in children, women of reproductive age, and other 
populations with low iron stores, there is often a correlation 
between parasite intensity and reductions in host hemoglobin 
[3,12,13,14,15,16]. In children, chronic heavy-intensity 
infections are associated with growth retardation, as well as 
intellectual and cognitive impairments; in pregnant women, 
they are associated with adverse maternal–fetal outcomes 
[3,12,13,14,15,16]. 
When measured in disability-adjusted life years, the global 
disease burden from hookworm exceeds all other major 
tropical infectious diseases with the exception of malaria, 
leishmaniasis, and lymphatic ﬁ lariasis (pp. 192–193 in [17]). 
In addition, hookworm has been associated with impaired 
learning, increased absences from school, and decreased 
future economic productivity [18]. Therefore, like other 
neglected diseases, chronic infection with hookworm 
promotes long-term disability and increases the likelihood 
that an afﬂ icted population will remain mired in poverty.
Hookworm Control Strategies
Because of its high transmission potential, hookworm has 
proven to be extremely difﬁ cult to eliminate or eradicate 
in areas of poverty and poor sanitation [19]. Indeed, in 
the absence of comprehensive economic development, the 
impact of sanitation, footwear, and health education has 
been minimal [19]. Control efforts have therefore shifted 
to reducing morbidity through mass treatment (also known 
as “deworming”) of affected populations with anthelminthic 
drugs [19].  
DOI: 10.1371/journal.pmed.0020067.g002
Figure 2. The Relationship between Poverty and Hookworm Prevalence
(Illustration: Margaret Shear, Public Library of Science, adapted 
from [4])
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Figure 1. Global Distribution of Human Hookworm Infection 
(Illustration: Margaret Shear, Public Library of Science, adapted from [4])
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Although benzimidazoles (BZAs) are the most commonly 
used agents for treating STH infections, levamisole and 
pyrantel may also be used in some circumstances. Periodic 
and repeated deworming with BZAs and praziquantel, 
complemented by basic sanitation and adequate safe water, 
is considered the most cost-effective means to control 
the morbidity caused by STH and schistosome infections 
[19,20,21,22]. Efforts led by the World Health Organization 
have focused on annual, twice-yearly, or thrice-yearly doses in 
schools because the heaviest intensities of STH infections are 
most commonly encountered in school-age children [23]. 
Among the health beneﬁ ts of periodic deworming of 
schoolchildren are improvements in iron and hemoglobin 
status, physical growth and ﬁ tness, and cognition 
[20,21,22,23]. In addition, there are important externalities, 
including improvements in education and reduced 
community-based transmission of ascaris and trichuris 
infections [23]. Accordingly, at the 54th World Health 
Assembly in 2001, a resolution was passed urging member 
states to attain a minimum target of regular deworming of at 
least 75% and up to 100% of all at-risk 
school-age children by 2010 [20,23]. 
Developing a New Control Tool: 
The Na-ASP-2 Hookworm Vaccine
Deworming satisﬁ es a number 
of United Nations Millennium 
Development Goals including those 
related to poverty reduction, child 
health, and education. However, there 
are also several reasons to believe that 
the school-based deworming programs 
could have less of an impact on the 
control of morbidity from hookworm 
than from other STH and schistosome 
infections [3]. As noted above, heavy-
intensity hookworm infections are 
common among both adults and 
children, so school-based programs 
would not be expected to have an 
impact on hookworm transmission 
in the community [24]. School-
based programs are also not likely to 
affect either preschool children or 
pregnant women, despite evidence 
for the health beneﬁ ts from BZAs 
in both populations [16,25]. Finally, 
a single dose of mebendazole (one 
of the two major BZAs) has variable 
efﬁ cacy against hookworm [26], and 
following treatment, hookworm re-
infection to pre-treatment levels can 
occur within 4–12 months [27]. This, 
and the observation that the efﬁ cacy of 
mebendazole against hookworm can 
diminish with frequent and repeated 
use, has prompted concerns about the 
possible emergence of BZA resistance 
[28]. 
As a complementary strategy, 
the Human Hookworm Vaccine 
Initiative (HHVI) is developing a 
safe, efﬁ cacious, and cost-effective vaccine, the Na-ASP-2 
Hookworm Vaccine, that would provide an additional tool 
for the control of hookworm [29,30]. The HHVI is a non-
proﬁ t partnership comprising research, process development, 
vaccine manufacturing and control, and pre-clinical and 
clinical testing units at the George Washington University, 
London School of Hygiene and Tropical Medicine, and 
Oswaldo Cruz Foundation (FIOCRUZ), and sponsored by the 
Sabin Vaccine Institute (www.sabin.org). 
The HHVI selected the hookworm larval antigen ASP-2 
(ancylostoma secreted protein-2) based on studies that (1) 
identiﬁ ed the molecule as a protective antigen linked to 
earlier-generation irradiated infective larval vaccines [29], 
(2) determined a relationship between human anti-ASP-2 
antibodies and reduced risk of heavy hookworm infection in 
populations living in hookworm-endemic regions of Brazil and 
China ([30]; J. Bethony, A. Loukas, M. J. Smout, S. Brooker, 
S. Mendez, et al., unpublished data), and (3) conﬁ rmed the 
ability of recombinant ASP-2 to partially protect laboratory 
animals against larval hookworm challenges [30,31,32]. 
DOI: 10.1371/journal.pmed.0020067.g003
Figure 3. Life Cycle of the Human Hookworm N. americanus
The BZA anthelminthics albendazole and mebendazole remove adult hookworms from 
the gastrointestinal tract. In contrast, the Na-ASP-2 Hoookworm Vaccine is designed to 
target third-stage infective larvae (ﬁ lariform larvae). Humoral immunity to the vaccine 
inhibits the entry of larvae into the gastrointestinal tract and thereby prevents their 
development into blood-feeding adult parasites. (Illustration: Sapna Khandwala, Public 
Library of Science, adapted from [3] and [33])
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Process development, cGMP manufacture and control, 
and pre-clinical testing of Na-ASP-2 from N. americanus were 
completed in 2004 (Figure 4). Pending United States Food 
and Drug Administration approval, clinical testing of the 
vaccine will take place in 2005. The Na-ASP-2 Hookworm 
Vaccine will be developed almost entirely in the non-proﬁ t 
sector. Ultimately, the vaccine will be indicated for the active 
immunization of susceptible individuals against moderate 
and heavy necator infection. Vaccination would reduce 
the number of hookworm infective larvae entering the 
gastrointestinal tract, thereby reducing the number of adult 
worms and the fecal egg counts in individuals exposed to the 
larvae. 
Hookworm as a Model
Because immunization would only affect hookworm 
larvae and not adult hookworms already residing in the 
gastrointestinal tract of infected individuals, the ﬁ rst 
dose of the vaccine would be administered following 
deworming. Therefore, use of the vaccine could build 
on the infrastructures developed as part of school-based 
programs. Given that hookworm afﬂ icts only the world’s most 
impoverished, a major hurdle for the development of the 
Na-ASP-2 Hookworm Vaccine is its small commercial market. 
Innovative ﬁ nancing mechanisms must be considered to 
produce this orphan biologic. Towards that end, the HHVI 
has partnered with manufacturers in hookworm-endemic 
middle-income countries that would commit to industrial 
scale-up of the Na-ASP-2 Hookworm Vaccine pending 
proof-of-principle for its efﬁ cacy. This approach might 
help to inform the development of business models for the 
production and distribution of orphan biologics for other 
neglected diseases. 
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